-
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
23 Apr 2024 12:42 GMT
… , the phase 3 trial “First Line IRESSA™ Versus Carboplatin… of the treatment of not only lung cancer, but of … While these two trials both include different drugs targeted at … Sciences, Takeda, Janssen, Blueprint Medicine, Mirati; non-financial support …
-
AstraZeneca announces positive results from ADRIATIC phase III trial of Imfinzi in patients with limited─stage small cell lung cancer
06 Apr 2024 05:12 GMT
… III immunotherapy trial to deliver significant … cancer treatments for patients with SCLC, NSCLC, bladder cancer, breast cancer, several gastrointestinal cancers … cancer medicines and the next wave of innovations, including Tagrisso (osimertinib) and Iressa …
-
25 drugs at Mark Cuban's online pharmacy with biggest cost reductions
06 Apr 2024 00:30 GMT
… Drugs now sells hundreds of generics and about 20 branded medications … pharmacy benefit managers.
Each drug is priced at its … medications with the biggest price cuts sold at Cost Plus Drugs … 203.95
Gefitinib (generic for Iressa)
Retail price: $7,041 …
-
Opinion: Personalized medicine: We’re not there yet
05 Apr 2024 12:53 GMT
… accessing the tests and treatments underpinning personalized medicine.
20 years of progress … drugs, though these approvals did provide proofs of principle.
Herceptin (trastuzumab), Iressa … of all clinical trials in cancer care are now for drugs that are …
-
AstraZeneca : Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial
21 Mar 2024 14:23 GMT
… by the Food and Drug Administration (FDA) based on these … Phase III trial in the 1st-line treatment of patients with … Phase II trials, and the SAFFRON Phase III trial, which … cancer medicines and the next wave of innovations, including Tagrisso and Iressa …
-
AstraZeneca's Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, stage III EGFR─mutated lung cancer in LAURA phase III trial
20 Feb 2024 07:03 GMT
… NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase … ORCHARD phase II trials, and the SAFFRON phase III trial, which test … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa …
-
Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
19 Feb 2024 08:27 GMT
… NSCLC are particularly sensitive to treatment with an EGFR-tyrosine kinase … ORCHARD Phase II trials, and the SAFFRON Phase III trial, which test … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa …
-
AstraZeneca's Tagrisso with addition of chemotherapy approved in US for patients with EGFR─mutated advanced lung cancer
19 Feb 2024 08:21 GMT
… by the Food and Drug Administration (FDA) was based on the … phase III trial in the 1st-line treatment of patients with … phase II trials, and the SAFFRON phase III trial, which … cancer medicines and the next wave of innovations, including Tagrisso and Iressa …
-
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
17 Feb 2024 03:05 GMT
… by the Food and Drug Administration (FDA) was based on the … -treated patients in clinical trials, 1.1% were found … Phase III trial in the 1st-line treatment of patients with … cancer medicines and the next wave of innovations, including TAGRISSO and IRESSA …
-
October - December 2023 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
04 Feb 2024 08:45 GMT
… labels that contribute to wrong drug errors
FDA is evaluating the need … prolonged
FDA is evaluating the need for regulatory action.
Gilotrif (afatinib)
Iressa … (gefitinib)
Tarceva (erlotinib)
Cardiac failure
FDA is evaluating the …